Abbott Laboratories (ABT) FY2025 Annual Balance Sheet

Abbott Laboratories (ABT) FY2025 Annual Balance Sheet

Balance sheet as of 2025-12-31. The chart shows assets, liabilities and equity at that date.

Assets

86,713,000,000 US dollars

Current assets

25,996,000,000 US dollars

Non-current assets

60,717,000,000 US dollars

Liabilities (calculated)

33,942,000,000 US dollars

Current liabilities

16,496,000,000 US dollars

Non-current liabilities

17,446,000,000 US dollars

Equity

52,771,000,000 US dollars

Noncontrolling interest

641,000,000 US dollars. Included in consolidated equity; this amount is not added again.

Land

541,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.

Buildings

4,543,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.

Equipment

17,571,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.

Construction in progress

2,567,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.

Less: accumulated depreciation and amortization

negative 13,406,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.

Cash and cash equivalents

8,522,000,000 US dollars

Trade receivables, less allowances of — 2025: $490; 2024: $439

7,929,000,000 US dollars

Finished products

3,976,000,000 US dollars

Other prepaid expenses and receivables

2,640,000,000 US dollars

Materials

1,608,000,000 US dollars

Work in process

904,000,000 US dollars

Investments, primarily bank time deposits and U.S. treasury bills

417,000,000 US dollars

Goodwill

24,035,000,000 US dollars

Deferred income taxes and other assets

18,422,000,000 US dollars

Net property and equipment

11,816,000,000 US dollars

Intangible assets, net of amortization

5,526,000,000 US dollars

Investments

918,000,000 US dollars

Other accrued liabilities

5,812,000,000 US dollars

Trade accounts payable

4,240,000,000 US dollars

Current portion of long-term debt

3,033,000,000 US dollars

Salaries, wages, and commissions

1,745,000,000 US dollars

Dividends payable

1,097,000,000 US dollars

Income taxes payable

569,000,000 US dollars

Long-term debt

9,896,000,000 US dollars

Post-employment obligations and other long-term liabilities

7,550,000,000 US dollars

Earnings employed in the business

49,781,000,000 US dollars

Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2025: 1,996,795,525; 2024: 1,991,472,630

25,527,000,000 US dollars

Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued

0 US dollars

Noncontrolling interests in subsidiaries

641,000,000 US dollars

Common shares held in treasury, at cost — Shares: 2025: 260,196,074; 2024: 259,774,639

negative 17,177,000,000 US dollars

Accumulated other comprehensive income (loss)

negative 6,001,000,000 US dollars

Gross equity (calculated)

75,949,000,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

• Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
• Treasury shares and other negative equity contributions reduce equity.